Abbott and Novo expand partnership to launch Plosbrio® broadening access to semaglutide for advanced diabetes care across Asia Pacific

·5h ago
Share:PostShare

The collaboration combines Novo's leadership in diabetes care medicines and GLP-1 therapies with Abbott's extensive healthcare and commercial footprint across the region Abbott will promote and distribute Plosbrio® (semaglutide) across a number of Asia Pacific countries, helping expand...

P

Pr Newswire Apac

Original source

Read full story

Related Stories

Business5h ago

Basic pension recipients with multiple citizenships more than double

The number of recipients of South Korea’s basic pension who also hold foreign citizenship more than doubled in four years, topping 8,000 in 2025, according to a National Assembly Budget Office report. The budget office warned that gaps in verifying overseas income and assets could lead to unequal treatment. Under a law promulgated in October, people applying for the basic pension from April 21, 2027, will generally need to have lived in South Korea for at least five years after turning 19. The n

TThe Korea Herald

Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.

Read Disclaimer